{
  "id": 18021347,
  "title": "STAT+: Servier’s $1.55 billion muscular dystrophy drug fails first major test",
  "url": "https://urgent.news/2026/11/03/stat-serviers-1-55-billion-muscular-dystrophy-drug-fails-first-major",
  "topic": "science",
  "section": "Science",
  "published": "2026-11-03T20:53:20.000Z",
  "source": {
    "name": "STAT News",
    "slug": "stat-news",
    "url": "https://www.statnews.com/2026/11/03/becker-muscular-dystrophy-servier-edgewise-sevasemten-fail/"
  },
  "original_language": "en",
  "account": "French pharmaceutical company Servier announced on Tuesday that an experimental drug, sevasemten, failed to show any benefits in a major Phase 3 trial for a rare form of muscular dystrophy called Becker muscular dystrophy. The drug was acquired by Servier for $1.55 billion in cash and additional potential milestone payments. The trial, known as GRAND CANYON, did not meet expectations for the drug's ability to slow the progression of the disease. This unexpected setback highlights the challenges faced by both Servier and patients with Becker muscular dystrophy, who currently lack any approved treatments. Despite showing promise in an earlier, smaller randomized study, the results from the pivotal trial do not align with previous positive findings. Servier is conducting a thorough analysis of the complete trial data, along with earlier clinical data, in order to gain further insights into the study's results.",
  "summary": "Servier reports a surprise setback for a drug being tested for a form of muscular dystrophy that lacks treatment.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}